Using an in vivo breast cancer model, Korangath et al. [181] recently demonstrated that conjugation of hydroxyethyl-starch-covered iron oxide NPs to trastuzumab increases accumulation in the tumor regardless of HER2 expression—in contrast to their in vitro effectiveness, which required HER2 expression. Here, ERBB2 is linked to neoplasm.